Showing 4721-4730 of 6411 results for "".
- Measuring ctDNA May Lead to Alternative Treatment Options and Better Outcomes in Advanced Melanomahttps://practicaldermatology.com/news/measuring-ctdna-may-lead-to-alternative-treatment-options-and-better-outcomes-in-advanced-melanoma/2462040/Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study found that measuring ctDNA in the blood of patients with BRAF wild-type (BRAF WT) s
- Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201https://practicaldermatology.com/news/cabaletta-bio-receives-fda-clearance-of-ind-application-for-treatment-of-systemic-sclerosis-with-caba-201/2462036/The U.S. Food and Drug Administration (FDA) is allowing Cabaletta Bio, Inc.’s third Investigational New Drug (IND) application for CABA-201 to proceed. for a Phase 1/2 study in patients with systemic sclerosis (SSc). CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell
- Abeona Submits BLA for RDEB Treatmenthttps://practicaldermatology.com/news/abeona-submits-bla-for-rdeb-treatment/2462026/Abeona Therapeutics Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). <
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,
- Exploring the Link Between Sex Hormones and Melanoma Riskhttps://practicaldermatology.com/news/exploring-the-link-between-sex-hormones-and-melanoma-risk/2462016/Researchers out of the University of Tennessee Health Science Center are beginning a study to determine whether sex hormones affect the risk of melanoma The team received a $423,500 grant from the National Institute of Environmental Health Sciences, part of the National Institutes of He
- Smart Ring May Objectively Measure Scratching Intensityhttps://practicaldermatology.com/news/smart-ring-may-objectively-measure-scratching-intensity/2462015/A new wearable device may objectively measure the intensity of scratching. Akhil Padmanabha, a PhD student in Carnegie Mellon University's (CMU)
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-base
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- CeraVe Funds New Derm Residency Position at George Washington Universityhttps://practicaldermatology.com/news/cerave-funds-new-derm-residency-position-at-george-washington-university/2462012/CeraVe is partnering with George Washington University to support a newly approved Accreditation Council for Graduate Medical Education (ACGME) residency spot in the school's Department of Dermatology Resident Program, slated to begin on July 1, 2024. "
- Beyond BSA: IPC, NPF Call Attention to Psoriasis Lesion Location on Q of Lhttps://practicaldermatology.com/news/beyond-bsa-ipc-npf-call-attention-to-psoriasis-lesion-location-on-q-of-l/2462007/The International Psoriasis Council (IPC) is partnering with the National Psoriasis Foundation (NPF) to call attention to the influence of psoriasis lesion locations on patients’ quality of life. The joint effort presents a study that delves into how psoriasis in specific areas